The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment

Eli Muchtar, Dragan Jevremovic, Angela Dispenzieri, David M Dingli, Francis K. Buadi, Martha Lacy, Wilson Gonsalves, Suzanne R. Hayman, Prashant Kapoor, Nelson Leung, Stephen J Russell, John A. Lust, Yi Lin, Ronald S. Go, Rajshekhar Chakraborty, Steven Zeldenrust, Shaji K Kumar, Robert A. Kyle, S Vincent Rajkumar, Morie Gertz

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Multiparametric flow cytometry (MFC) in amyloid light-chain (AL) amyloidosis has not been widely adopted and, consequently, there is little information on its clinical relevance. We studied 173 patients with AL amyloidosis who underwent MFC immunophenotyping of bone marrow sample at diagnosis and 82 patients at the end of the first line of treatment (EOT). The number of monotypic plasma cells (PCs) and the polytypic PCs/bone marrow PCs (pPCs/BMPCs) ratio were analyzed. At diagnosis, ≥2.5% monotypic PCs was associated with a shorter progression-free survival (PFS) and overall survival (OS) compared with patients with <2.5% monotypic PCs (2-year PFS 41% vs 56%, P = .007; 2-year OS 55% vs 70%; P = .01). Additionally, patients with a pPCs/BMPCs ratio of ≤5% had a shorter PFS compared with patients with pPCs/BMPCs ratio >5% (2-year PFS 43% vs 55%; P = .02), but without OS difference (2-year OS 60% vs 67%; P = .19). In a multivariate analysis, the monotypic PCs retained an independent prediction for PFS/OS, whereas the pPCs/BMPCs ratio retained significance only for PFS. At EOT, ≥0.1% monotypic PCs was associated with a shorter PFS and OS compared with patients with <0.1% monotypic PCs (2-year PFS 31% vs 87%; P < .0001; 2-year OS 87% vs 98%, P = .02). In a subgroup analysis among patients who attained a very good partial response or better, the monotypic PCs at the 0.1% cutoff was predictive for progression rate but not for PFS/OS. MFC is prognostic for AL amyloidosis at diagnosis and at EOT. MFC may have a role in the definition of hematologic response.

Original languageEnglish (US)
Pages (from-to)82-87
Number of pages6
JournalBlood
Volume129
Issue number1
DOIs
StatePublished - Jan 5 2017

Fingerprint

Flow cytometry
Amyloidosis
Plasma Cells
Amyloid
Flow Cytometry
Disease-Free Survival
Plasmas
Light
Survival
Bone
Therapeutics
Bone Marrow
Immunophenotyping
Bone Marrow Cells
Multivariate Analysis

ASJC Scopus subject areas

  • Immunology
  • Biochemistry
  • Hematology
  • Cell Biology

Cite this

The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. / Muchtar, Eli; Jevremovic, Dragan; Dispenzieri, Angela; Dingli, David M; Buadi, Francis K.; Lacy, Martha; Gonsalves, Wilson; Hayman, Suzanne R.; Kapoor, Prashant; Leung, Nelson; Russell, Stephen J; Lust, John A.; Lin, Yi; Go, Ronald S.; Chakraborty, Rajshekhar; Zeldenrust, Steven; Kumar, Shaji K; Kyle, Robert A.; Rajkumar, S Vincent; Gertz, Morie.

In: Blood, Vol. 129, No. 1, 05.01.2017, p. 82-87.

Research output: Contribution to journalArticle

@article{12141bac97b74d358a9623adc656c410,
title = "The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment",
abstract = "Multiparametric flow cytometry (MFC) in amyloid light-chain (AL) amyloidosis has not been widely adopted and, consequently, there is little information on its clinical relevance. We studied 173 patients with AL amyloidosis who underwent MFC immunophenotyping of bone marrow sample at diagnosis and 82 patients at the end of the first line of treatment (EOT). The number of monotypic plasma cells (PCs) and the polytypic PCs/bone marrow PCs (pPCs/BMPCs) ratio were analyzed. At diagnosis, ≥2.5{\%} monotypic PCs was associated with a shorter progression-free survival (PFS) and overall survival (OS) compared with patients with <2.5{\%} monotypic PCs (2-year PFS 41{\%} vs 56{\%}, P = .007; 2-year OS 55{\%} vs 70{\%}; P = .01). Additionally, patients with a pPCs/BMPCs ratio of ≤5{\%} had a shorter PFS compared with patients with pPCs/BMPCs ratio >5{\%} (2-year PFS 43{\%} vs 55{\%}; P = .02), but without OS difference (2-year OS 60{\%} vs 67{\%}; P = .19). In a multivariate analysis, the monotypic PCs retained an independent prediction for PFS/OS, whereas the pPCs/BMPCs ratio retained significance only for PFS. At EOT, ≥0.1{\%} monotypic PCs was associated with a shorter PFS and OS compared with patients with <0.1{\%} monotypic PCs (2-year PFS 31{\%} vs 87{\%}; P < .0001; 2-year OS 87{\%} vs 98{\%}, P = .02). In a subgroup analysis among patients who attained a very good partial response or better, the monotypic PCs at the 0.1{\%} cutoff was predictive for progression rate but not for PFS/OS. MFC is prognostic for AL amyloidosis at diagnosis and at EOT. MFC may have a role in the definition of hematologic response.",
author = "Eli Muchtar and Dragan Jevremovic and Angela Dispenzieri and Dingli, {David M} and Buadi, {Francis K.} and Martha Lacy and Wilson Gonsalves and Hayman, {Suzanne R.} and Prashant Kapoor and Nelson Leung and Russell, {Stephen J} and Lust, {John A.} and Yi Lin and Go, {Ronald S.} and Rajshekhar Chakraborty and Steven Zeldenrust and Kumar, {Shaji K} and Kyle, {Robert A.} and Rajkumar, {S Vincent} and Morie Gertz",
year = "2017",
month = "1",
day = "5",
doi = "10.1182/blood-2016-06-721878",
language = "English (US)",
volume = "129",
pages = "82--87",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment

AU - Muchtar, Eli

AU - Jevremovic, Dragan

AU - Dispenzieri, Angela

AU - Dingli, David M

AU - Buadi, Francis K.

AU - Lacy, Martha

AU - Gonsalves, Wilson

AU - Hayman, Suzanne R.

AU - Kapoor, Prashant

AU - Leung, Nelson

AU - Russell, Stephen J

AU - Lust, John A.

AU - Lin, Yi

AU - Go, Ronald S.

AU - Chakraborty, Rajshekhar

AU - Zeldenrust, Steven

AU - Kumar, Shaji K

AU - Kyle, Robert A.

AU - Rajkumar, S Vincent

AU - Gertz, Morie

PY - 2017/1/5

Y1 - 2017/1/5

N2 - Multiparametric flow cytometry (MFC) in amyloid light-chain (AL) amyloidosis has not been widely adopted and, consequently, there is little information on its clinical relevance. We studied 173 patients with AL amyloidosis who underwent MFC immunophenotyping of bone marrow sample at diagnosis and 82 patients at the end of the first line of treatment (EOT). The number of monotypic plasma cells (PCs) and the polytypic PCs/bone marrow PCs (pPCs/BMPCs) ratio were analyzed. At diagnosis, ≥2.5% monotypic PCs was associated with a shorter progression-free survival (PFS) and overall survival (OS) compared with patients with <2.5% monotypic PCs (2-year PFS 41% vs 56%, P = .007; 2-year OS 55% vs 70%; P = .01). Additionally, patients with a pPCs/BMPCs ratio of ≤5% had a shorter PFS compared with patients with pPCs/BMPCs ratio >5% (2-year PFS 43% vs 55%; P = .02), but without OS difference (2-year OS 60% vs 67%; P = .19). In a multivariate analysis, the monotypic PCs retained an independent prediction for PFS/OS, whereas the pPCs/BMPCs ratio retained significance only for PFS. At EOT, ≥0.1% monotypic PCs was associated with a shorter PFS and OS compared with patients with <0.1% monotypic PCs (2-year PFS 31% vs 87%; P < .0001; 2-year OS 87% vs 98%, P = .02). In a subgroup analysis among patients who attained a very good partial response or better, the monotypic PCs at the 0.1% cutoff was predictive for progression rate but not for PFS/OS. MFC is prognostic for AL amyloidosis at diagnosis and at EOT. MFC may have a role in the definition of hematologic response.

AB - Multiparametric flow cytometry (MFC) in amyloid light-chain (AL) amyloidosis has not been widely adopted and, consequently, there is little information on its clinical relevance. We studied 173 patients with AL amyloidosis who underwent MFC immunophenotyping of bone marrow sample at diagnosis and 82 patients at the end of the first line of treatment (EOT). The number of monotypic plasma cells (PCs) and the polytypic PCs/bone marrow PCs (pPCs/BMPCs) ratio were analyzed. At diagnosis, ≥2.5% monotypic PCs was associated with a shorter progression-free survival (PFS) and overall survival (OS) compared with patients with <2.5% monotypic PCs (2-year PFS 41% vs 56%, P = .007; 2-year OS 55% vs 70%; P = .01). Additionally, patients with a pPCs/BMPCs ratio of ≤5% had a shorter PFS compared with patients with pPCs/BMPCs ratio >5% (2-year PFS 43% vs 55%; P = .02), but without OS difference (2-year OS 60% vs 67%; P = .19). In a multivariate analysis, the monotypic PCs retained an independent prediction for PFS/OS, whereas the pPCs/BMPCs ratio retained significance only for PFS. At EOT, ≥0.1% monotypic PCs was associated with a shorter PFS and OS compared with patients with <0.1% monotypic PCs (2-year PFS 31% vs 87%; P < .0001; 2-year OS 87% vs 98%, P = .02). In a subgroup analysis among patients who attained a very good partial response or better, the monotypic PCs at the 0.1% cutoff was predictive for progression rate but not for PFS/OS. MFC is prognostic for AL amyloidosis at diagnosis and at EOT. MFC may have a role in the definition of hematologic response.

UR - http://www.scopus.com/inward/record.url?scp=85014970454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014970454&partnerID=8YFLogxK

U2 - 10.1182/blood-2016-06-721878

DO - 10.1182/blood-2016-06-721878

M3 - Article

C2 - 27729322

AN - SCOPUS:85014970454

VL - 129

SP - 82

EP - 87

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -